Andrew Zelenetz, MD, PhD | Authors

Determining the Cell of Origin in DLBCL

September 26, 2018

Dr. Andrew Zelenetz spoke with Cancer Network about the importance of determining the cell of origin in patients with DLBCL.

Selective benefit in high-risk patients, but won’t alter clinical practice

September 01, 2008

The basis for the increased risks of cytomegalovirus and P. carinii infections with DENSE-R-CHOP-14 was puzzling, said Dr. Zelenetz of Memorial Sloan Kettering Cancer Center.